Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Hans Jaeger, Edgar T. Overton, Gary Richmond, Giuliano Rizzardini, Jaime Andrade‐Villanueva, Rosie Mngqibisa, Antonio Ocampo Hermida, Anders Thalme, Elena Belonosova, Faïza Ajana, Paul Benn, Yuanyuan Wang, Krischan J Hudson, Carlos Martín Español, Susan L. Ford, Herta Crauwels, David A. Margolis, Christine L. Talarico, Kimberly Y. Smith, Veerle Van Eygen, Rodica Van Solingen‐Ristea, Simon Vanveggel, William Spreen